MAZE today
$36.73+$1.28 (+3.61%)close Nov 11, 2026Trend
DailyUptrend (confirmed)
4 hourStrong Bullish
1 hourStrong Bullish
15 minBearish
5 minDescending Triangle
Daily trend turns down below $25.96
Key levels
Resistance$42.17
Resistance$37.37
Support$34.73
Support$32.63
Latest news & SEC filings
AnalystJP Morgan keeps Overweight rating on Maze Therapeutics, cuts price target to $51
AnalystWedbush keeps Outperform rating on Maze Therapeutics, lifts target to $49
All MAZE news →About Maze Therapeutics
Maze Therapeutics is a drug developer that mines population genetic data to create oral treatments for disorders of the kidney and metabolism. Its most advanced candidate, MZE829, blocks the APOL1 protein and is in mid-stage testing for a hereditary form of kidney disease. A second candidate, MZE782, is being readied for trials in phenylketonuria and chronic kidney disease. The company also licenses out earlier-stage programs, including one for Pompe disease partnered with Shionogi.
Based on the company's 10-K filed Mar 25, 2026.
Nasdaq · Healthcare
Maze Therapeutics, Inc. (MAZE)
What Is the Price Target for MAZE?
SEPT Low Target
$50.00
SEPT Mid Target
$69.50
SEPT High Target
$110.00
Analyst Consensus
$69.50
Is MAZE a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MAZE.
Start Free Trial →Is MAZE Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B, Analyst Consensus
Fair Value
$56.84
12
Moat Score
NONE
3/9
Piotroski Score
18.0
Altman Z-Score
What Is Smart Money Doing with MAZE?
Insider Signal
SELLING
0 buys / 17 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Coloma Jason V | director officer | Sale | 2,257 | $68K | Nov 2, 2026 |
| Coloma Jason V | director officer | Sale | 336 | $10K | Nov 2, 2026 |
| Coloma Jason V | director officer | Sale | 26,563 | $799K | Nov 2, 2026 |
| Coloma Jason V | director officer | Sale | 5,345 | $166K | Nov 2, 2026 |
| Dandekar Atul | officer | Buy | 6,643 | $69K | Oct 29, 2026 |
| Dandekar Atul | officer | Buy | 857 | $9K | Oct 29, 2026 |
| Dandekar Atul | officer | Sale | 7,500 | $241K | Oct 29, 2026 |
| Dandekar Atul | officer | Buy | 7,500 | $78K | Sep 29, 2026 |
| Dandekar Atul | officer | Sale | 7,500 | $203K | Sep 29, 2026 |
| Bernstein Harold | officer | Sale | 9,705 | $255K | Sep 4, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MAZE Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-344%
FCF Growth YoY
-250.7%
Revenue Trend
UNKNOWN
Dark Pool Trades for MAZE
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MAZE, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:01:06 | $36.73 | 8,219 | $$302K | SELL |
| 21:00:18 | $36.73 | 3,328 | $$122K | SELL |
| 21:00:18 | $36.73 | 4,277 | $$157K | SELL |
| 19:13:57 | $36.70 | 2,512 | $$92K | SELL |
| 19:09:51 | $37.00 | 2,139 | $$79K | BUY |
5 dark pool trades shown · $$753K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for MAZE
PREVIEWSEPT Investing provides real-time options flow tracking for MAZE, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $30 | Nov 20 | 9 | $$700 | 1 | SWEEP |
1 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Maze Therapeutics, Inc. (MAZE) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MAZE — frequently asked questions
What is MAZE stock price today?
Maze Therapeutics, Inc. (MAZE) is at $36.73, up 3.61% (+$1.28) at the Nov 11, 2026 close.
Why is MAZE stock moving today?
Latest MAZE news — Nov 11, 2026: JP Morgan keeps Overweight rating on Maze Therapeutics, cuts price target to $51 · Nov 10, 2026: Wedbush keeps Outperform rating on Maze Therapeutics, lifts target to $49
Why did MAZE stock move on Oct 19, 2026?
Maze Therapeutics shares rose 6.03% to close at $29.70 after Canaccord Genuity initiated coverage with a Buy rating and a $75 price target. The stock traded between a low of $27.83 and a high of $30.57 on volume of about 1.28 million shares.
What is the MAZE price target?
The average analyst price target for MAZE is $69.50, ranging from $50 to $110, based on 6 analysts. Latest: Canaccord Genuity initiates on Oct 19, 2026.
What do analysts rate MAZE?
Analyst ratings for MAZE: 14 Buy, 0 Hold, 0 Sell — consensus Strong Buy.
Did MAZE beat earnings?
MAZE last reported on Aug 11, 2026: EPS -$0.76 vs -$0.72 expected — a miss of 6.0%.
Does MAZE pay a dividend?
MAZE does not currently pay a dividend.
How much debt does MAZE have?
Maze Therapeutics, Inc. reported $39M of debt and $203M of cash (Jun 30, 2026).
What are MAZE support and resistance levels?
Support: $34.73, $32.63, $29.75. Resistance: $37.37, $42.17, $46.67.
What are insiders doing with MAZE?
Insider activity: SELLING, 0 buys and 17 sells in the last 90 days.
What is the latest news on MAZE?
Nov 11, 2026: JP Morgan keeps Overweight rating on Maze Therapeutics, cuts price target to $51 · Nov 10, 2026: Wedbush keeps Outperform rating on Maze Therapeutics, lifts target to $49